Anti-CTLA-4 antibodies and methods of use thereof
US12246066B2 · kind B2 · utility
0Cited by
61References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 21, 2023 |
| Grant date | Mar 11, 2025 |
| Priority date | — |
| Expiry date | Mar 21, 2043 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.